The Cancer Drugs Fund in practice and under the new framework

by Symmetron | Apr 16, 2019

CAncer   The cancer drugs fund in practice and under the new framework PharmacoEconomics. 2019:1-10. Authors Sabry-Grant C, Malottki K, Diamantopoulos A Noteworthy This is the first study investigating the Cancer Drugs Fund under the new framework. We developed a...

Research methods to change clinical practice for patients with rare cancers

by Symmetron | Jan 21, 2019

Cancer   Research methods to change clinical practice for patients with rare cancers The Lancet Oncology. 2016;17(2):e70-e80 Authors Billingham L, Malottki K, Steven N Noteworthy This paper describes research methods that are relevant for rare cancers in relation to...

Providing public health information to prevent skin cancer: review of effectiveness and cost-effectiveness

by Symmetron | Jan 21, 2019

Cancer Providing public health information to prevent skin cancer: review of effectiveness and cost-effectiveness National Institute for Health and Care Excellence. Public Health Guidance 32. February 2009 Authors Malottki K, Wang D, Andronis L, Barton P, Fry-Smith A,...

An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom

by Symmetron | Jan 21, 2019

Cancer An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom Value in Health. 2008;11(5):791-9 Authors Brown B, Diamantopoulos A, Bernier J,...

An indirect treatment comparison of cabozantinib verse vandetanib in progressive medullary thyroid cancer (MTC)

by Symmetron | Jan 21, 2019

Cancer An Indirect Treatment Comparison of Cabozantinib Verse Vandetanib in Progressive Medullary Thyroid Cancer (MTC) Value in Health. 2014;17(7):A616-7 Authors Rinciog C, Myrén KJ, Aldén M, Diamantopoulos A, LeReun C Process \ Systematic review and adjusted...